Related Experiment Video

Updated: Jul 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Slaked lime and betel nut cancer in Papua New Guinea

K S Kiyingi

    Lancet (London, England)
    |November 28, 1992
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
    07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
    07:44

    Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

    Published on: March 25, 2022

    Related Experiment Videos

    Last Updated: Jul 6, 2026

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
    07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
    07:44

    Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

    Published on: March 25, 2022

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    How much do outpatients know about drugs prescribed to them? A pilot study.

    Papua and New Guinea medical journal·1993

    Drugs in the home: danger and waste.

    World health forum·1993

    Compliance profiles of paediatric patients in an outpatient department.

    Papua and New Guinea medical journal·1992

    Betel-nut chewing may aggravate asthma.

    Papua and New Guinea medical journal·1991

    Ewing's sarcoma: fifteen years' experience at Angau Memorial Hospital.

    Papua and New Guinea medical journal·1990

    Beta-adrenoceptor blockade with propranolol and bronchial responsiveness to a number of bronchial provocation tests in non-asthmatic subjects.

    European journal of respiratory diseases·1985

    8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

    Lancet (London, England)·2026

    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

    Lancet (London, England)·2026

    A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

    Lancet (London, England)·2026

    Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

    Lancet (London, England)·2026

    Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lancet (London, England)·2026

    Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

    Lancet (London, England)·2026

    Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Resection of Liver Metastasis from Lacrimal Gland Adenoid Cystic Carcinoma: A Case Report and Review of the Literature.

    Surgical case reports·2026

    Biopsy-Proven Prostatic Metastasis From Diffuse-Type Gastric Adenocarcinoma Presenting With Bilateral Malignant Ureteric Obstruction: A Case Report.

    Cureus·2026

    Adult Recurrent Wilms' Tumor Presenting as a Large Mass: A Case Report and Current Literature Review.

    Sisli Etfal Hastanesi tip bulteni·2026

    Mast Cell Metabolism: A Viable Therapeutic Target against Intraoral Neurofibroma.

    Journal of microscopy and ultrastructure·2026

    Small Intestinal Bacterial Overgrowth Following Gastrointestinal Cancer Surgery: Current Evidence and Future Perspectives.

    Annals of gastroenterological surgery·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us